Antisense Therapeutics Limited (ANP.AX)
| Previous close | 0.0850 |
| Open | 0.0850 |
| Bid | 0.0810 x 50000000 |
| Ask | 0.0830 x 34112000 |
| Day's range | 0.0820 - 0.0850 |
| 52-week range | 0.0780 - 0.3500 |
| Volume | |
| Avg. volume | 736,662 |
| Market cap | 54.841M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0150 |
| Earnings date | 23 Aug 2022 - 29 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.57 |
- GlobeNewswire
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2
Figure 1 Quad RNA ddPCR (Pooled) Figure 2 Quad RNA ddPCR (Female) LGMDR2, also referred to as dysferlinopathy, is a rare genetic muscle disease caused by mutations in the dysferlin gene (DYSF)Animal study conducted at MCRI in collaboration with Jain Foundation in the USStudy results showed significant decreases in target CD49d RNA and key immune cell RNA levels in the muscleData supports progression into a longer-term efficacy study planned for 3Q/4Q2022 Mark Diamond, Antisense Therapeutics Mana
- GlobeNewswire
Antisense Therapeutics to present poster at world’s largest NMD conference
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George Tachas, the Company’s Director of Drug Discovery and Patents, will present an e-poster on new data from its Phase II study of ATL1102 in patients with Duchenne muscular dystrophy (DMD). DMD is a rare genetic disorder th
- Simply Wall St.
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
